JP4532900B2 - 細菌またはウイルス感染症の予防または治療における乳清アポタンパク質の使用 - Google Patents

細菌またはウイルス感染症の予防または治療における乳清アポタンパク質の使用 Download PDF

Info

Publication number
JP4532900B2
JP4532900B2 JP2003522566A JP2003522566A JP4532900B2 JP 4532900 B2 JP4532900 B2 JP 4532900B2 JP 2003522566 A JP2003522566 A JP 2003522566A JP 2003522566 A JP2003522566 A JP 2003522566A JP 4532900 B2 JP4532900 B2 JP 4532900B2
Authority
JP
Japan
Prior art keywords
acid
whey
mixture
apoprotein
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003522566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501863A (ja
JP2005501863A5 (https=
Inventor
マイケル・アンソニー・フォラン
ダミアン・ブレイディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Westgate Biological Ltd
Original Assignee
Westgate Biological Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Westgate Biological Ltd filed Critical Westgate Biological Ltd
Publication of JP2005501863A publication Critical patent/JP2005501863A/ja
Publication of JP2005501863A5 publication Critical patent/JP2005501863A5/ja
Application granted granted Critical
Publication of JP4532900B2 publication Critical patent/JP4532900B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
JP2003522566A 2001-08-23 2002-08-20 細菌またはウイルス感染症の予防または治療における乳清アポタンパク質の使用 Expired - Fee Related JP4532900B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IES20010780 2001-08-23
PCT/IE2002/000121 WO2003018049A2 (en) 2001-08-23 2002-08-20 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection

Publications (3)

Publication Number Publication Date
JP2005501863A JP2005501863A (ja) 2005-01-20
JP2005501863A5 JP2005501863A5 (https=) 2006-01-05
JP4532900B2 true JP4532900B2 (ja) 2010-08-25

Family

ID=11042830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003522566A Expired - Fee Related JP4532900B2 (ja) 2001-08-23 2002-08-20 細菌またはウイルス感染症の予防または治療における乳清アポタンパク質の使用

Country Status (15)

Country Link
US (2) US7687074B2 (https=)
EP (1) EP1427436B1 (https=)
JP (1) JP4532900B2 (https=)
KR (1) KR100907959B1 (https=)
CN (1) CN1578670B (https=)
AT (1) ATE399562T1 (https=)
AU (1) AU2002356112B2 (https=)
CA (1) CA2458146C (https=)
DE (1) DE60227389D1 (https=)
DK (1) DK1427436T3 (https=)
ES (1) ES2309228T3 (https=)
NZ (1) NZ531639A (https=)
PT (1) PT1427436E (https=)
RU (1) RU2305547C2 (https=)
WO (1) WO2003018049A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2863168A1 (fr) * 2003-12-04 2005-06-10 Centre Nat Rech Scient Utilisation d'inducteurs de la voie de degradation de la gamma-butyrolactone pour inactiver le signal n-acy homoserine lactone.
BRPI0512864B8 (pt) * 2004-07-01 2021-05-25 Johnson & Johnson Vision Care composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição
WO2007035870A2 (en) * 2005-09-20 2007-03-29 Prolacta Bioscience, Inc. A method for testing milk
WO2007061942A2 (en) 2005-11-18 2007-05-31 Glanbia Nutritionals (Ireland) Ltd. Compositions for disrupting and inhibiting reconstitution of wound biofilm
JP5017531B2 (ja) * 2006-09-11 2012-09-05 株式会社アップウェル 口内清浄剤
KR20100108526A (ko) * 2007-12-04 2010-10-07 웨스트게이트 바이올로지컬 리미티드 지방산 및 우유 단백질을 포함하는 항균성 조성물
JP2009190994A (ja) * 2008-02-13 2009-08-27 Kitasato Institute 抗インフルエンザウイルス剤、及びその有効成分の製造方法
US20090311236A1 (en) * 2008-06-11 2009-12-17 Immune @Work, Inc. Therapeutic Peptide Compositions And Methods Of Making And Using Same
EP2316445A4 (en) * 2008-06-11 2011-12-21 Ricom Corp HUMAN BETA3 ADRENERGER RECEPTOR LIGAND AND THEREOF FOOD OR PHARMACEUTICAL PREPARATION
US8808345B2 (en) * 2008-12-31 2014-08-19 Medtronic Ardian Luxembourg S.A.R.L. Handle assemblies for intravascular treatment devices and associated systems and methods
WO2010082587A1 (ja) * 2009-01-13 2010-07-22 株式会社大気倶楽部 空中懸濁物吸着剤
KR101119538B1 (ko) * 2009-06-10 2012-02-22 장선호 시알릭산-함유 유청 단백질을 유효성분으로 함유하는 인플루엔자 바이러스 감염증의 예방 및 치료용 조성물
ES2643862T3 (es) * 2009-11-17 2017-11-24 Michael Anthony Folan Composiciones antimicrobianas que contienen ácidos grasos libres
AR082943A1 (es) * 2010-08-06 2013-01-23 Aptalis Pharma Ltd Formula nutricional predigerida
KR101355018B1 (ko) * 2010-12-13 2014-01-24 노부오 구보 시알릭산-함유 유청 단백질을 유효성분으로 함유하는 인플루엔자 바이러스 감염증의 예방용 동물사료 첨가제 및 이를 포함하는 동물사료용 조성물
RU2494726C2 (ru) * 2011-04-11 2013-10-10 Общество с Ограниченной Ответственностью "Производственная Торговая Компания "Лактив" Способ профилактики и лечения грибковой инфекции у больных с голосовыми протезами
EP3150257A1 (en) * 2015-09-30 2017-04-05 Buga, Doris A method for producing a composition for strengthening the immune system
CA3026402A1 (en) 2017-12-05 2019-06-05 James F. Kane Water-soluble cannabinoids and methods of making same
US11298379B2 (en) * 2020-04-16 2022-04-12 James F. Kane Compositions comprising milk fat globules and methods of making same
CN113855787A (zh) * 2020-06-30 2021-12-31 北京大学 乳清蛋白作为冠状病毒广谱抑制剂的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2796378A (en) * 1954-04-09 1957-06-18 Jr Edgar A Ferguson Methionine free reaction product of a water-soluble copper salt and lactalbumin hydrolysate as fungicide
GB1050756A (https=) * 1964-09-10 1900-01-01
US4397927A (en) * 1982-03-25 1983-08-09 Brog Roy A Imitation milk compositions and aqueous dispersions prepared therefrom
EP0210204B1 (de) 1985-01-18 1988-12-07 Kailash Kumar Dr. Prof. Gauri Proteinhydrolysate, verfahren zu ihrer herstellung und arzneimittel, die diese hydrolysate enthalten
JPS62249931A (ja) 1986-04-21 1987-10-30 Morinaga Milk Ind Co Ltd 抗菌性組成物
JPH085798B2 (ja) * 1987-02-02 1996-01-24 紀夫 多田 抗菌剤
DE69003014T2 (de) * 1989-06-07 1993-12-16 Kao Corp Essbare Öl-in-Wasser-Emulsion.
JP2673320B2 (ja) * 1990-01-25 1997-11-05 雪印乳業株式会社 う蝕原菌付着阻止剤
JPH04159232A (ja) * 1990-08-21 1992-06-02 Yakult Honsha Co Ltd 日和見感染症予防・治療用経口組成物
CA2094570A1 (en) 1992-05-27 1993-11-28 Jerome F. Trumbetas Enzymatic protein process and product
CA2148261A1 (en) 1992-10-30 1994-05-11 Jerry A. Peterson Anti-diarrheic product and method of treating rotavirus-associated infection
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
US6197356B1 (en) * 1993-08-03 2001-03-06 Immunopath Profile, Inc. Process for preparing hypoallergenic foods
AU7792294A (en) * 1994-08-16 1996-03-07 Hemant Sabharwal Antibacterial composition containing multimeric alpha-lactalbumin
JP4233615B2 (ja) * 1996-08-22 2009-03-04 森永乳業株式会社 経口抗ヒト爪白癬及び／又は爪白癬以外のヒト足部白癬用医薬品
DE69824150T2 (de) 1997-01-09 2005-05-25 Morinaga Milk Industry Co. Ltd. Lactoferrin-tabletten
IE970541A1 (en) 1997-07-25 1999-01-27 Michael Anthony Folan Maternal immune secretions and their use in the treatment and/or prophylaxis of the buccal cavity
JP4129566B2 (ja) * 1997-09-05 2008-08-06 大塚製薬株式会社 肝臓脂肪蓄積抑制組成物及び肝臓脂肪蓄積抑制用食品添加剤
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AUPP051497A0 (en) 1997-11-24 1997-12-18 University Of Melbourne, The Antimicrobial peptides
US6126955A (en) * 1998-04-16 2000-10-03 University Of Utah Research Foundation Apo-transferrin as a potent inhibitor of bacterial adhesion to biomaterials
ATE259654T1 (de) 1998-06-26 2004-03-15 Nutricia Nv Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
JP2000119257A (ja) * 1998-08-14 2000-04-25 Nippon Nohyaku Co Ltd ピリダジノン誘導体
GB9903584D0 (en) 1999-02-18 1999-04-07 Univ Leeds Modified calycins
JP3662445B2 (ja) * 1999-06-30 2005-06-22 花王株式会社 油中水型乳化油脂組成物
WO2002094035A1 (en) * 2001-05-23 2002-11-28 Nutricopia, Inc. Nutritional frozen dessert and methods of manufacture
US20030165606A1 (en) 2001-07-18 2003-09-04 Lasekan John B. Anti-regurgitation formula and uses thereof
EP1319407A1 (en) * 2001-12-14 2003-06-18 Montoie Import-Export S.A. Pharmaceutical composition for topical treatment of skin disorders and skin wounds

Also Published As

Publication number Publication date
KR20040041579A (ko) 2004-05-17
DE60227389D1 (de) 2008-08-14
WO2003018049A2 (en) 2003-03-06
CN1578670B (zh) 2013-09-04
JP2005501863A (ja) 2005-01-20
CA2458146A1 (en) 2003-03-06
NZ531639A (en) 2006-02-24
EP1427436A2 (en) 2004-06-16
ES2309228T3 (es) 2008-12-16
KR100907959B1 (ko) 2009-07-16
EP1427436B1 (en) 2008-07-02
US7687074B2 (en) 2010-03-30
CA2458146C (en) 2012-07-24
US7972629B2 (en) 2011-07-05
RU2305547C2 (ru) 2007-09-10
AU2002356112B2 (en) 2007-11-08
US20050042299A1 (en) 2005-02-24
RU2004108040A (ru) 2005-09-27
CN1578670A (zh) 2005-02-09
WO2003018049A3 (en) 2003-11-06
PT1427436E (pt) 2008-09-08
US20100209526A1 (en) 2010-08-19
DK1427436T3 (da) 2008-10-13
ATE399562T1 (de) 2008-07-15

Similar Documents

Publication Publication Date Title
JP4532900B2 (ja) 細菌またはウイルス感染症の予防または治療における乳清アポタンパク質の使用
EP0629347B1 (en) Antibacterial agent and treatment of article therewith
AU2002356112A1 (en) Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
US8338363B2 (en) Pharmaceutical compositions comprising casein derived peptides and methods of use thereof
JP2673320B2 (ja) う蝕原菌付着阻止剤
JPWO2010041400A1 (ja) バイオフィルム形成抑制剤
US20190134168A1 (en) Combination, Therapeutic Uses And Prophylactic Uses
JP2832517B2 (ja) 大腸菌付着阻止剤
JP2013510799A (ja) 抗バイオフィルム糖ペプチド
US20250295739A1 (en) Combination, therapeutic uses and prophylactic uses
AU2012200889B2 (en) Pharmaceutical compositions comprising casein derived peptides and methods of use thereof
Pandya et al. Evaluating antimicrobial efficacy of bovine colostrum in patients suffering from periodontal disease: An invitro study
IL187120A (en) Casein-derived peptides and methods for their use in the herd's interface with milk
IL222487A (en) Casein-derived peptides and methods for using them to increase milk yield
IL222486A (en) Casein-derived peptides and methods for using them to enhance milk cleanliness

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090714

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091013

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091020

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100518

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100611

R150 Certificate of patent or registration of utility model

Ref document number: 4532900

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130618

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees